🍁 civid v1

Purpose and status

• Bill S-201 would require the Minister of Health to develop a national framework to support people with sickle cell disease, their families and caregivers.
• The provided text says the bill was passed by the Senate on November 18, 2025; the listed stage is first reading.

National framework

• The framework must address health professionals’ training, education, diagnostic and treatment tool needs, and set evidence-based national standards for diagnosis and treatment.
• It must provide for a national research network, improved data collection and a national registry.
• It must include measures for universal neonatal screening, postnatal diagnosis when necessary, and provision of results to affected individuals and organizations.
• It must address public awareness and blood donation, including measures to promote a diverse blood supply for safe transfusions.
• It must analyze a potential tax credit for people with sickle cell disease and their caregivers, and the potential inclusion of essential treatments in public drug insurance plans. It must also ensure sickle cell disease is included in eligibility criteria for existing disability benefits.
• The minister must consult relevant federal ministers, provincial and territorial representatives, stakeholders—including self-advocates, caregivers, service providers and medical and research representatives—and others the minister considers appropriate.

Reports and deadlines

• Within one year after the Act comes into force, the minister must prepare a report setting out the framework. It must be tabled in each House of Parliament within the first 15 sitting days of that House after the report is completed, and published on the Department of Health website within 10 days after tabling.
• Within three years after the framework report is tabled, the minister must table a further report in each House. It must describe implemented measures and their effectiveness, and explain why any measures remain unimplemented and the timeline for implementing them.

Existing law and costs

• The provided text does not identify amendments to existing statutes or specify funding or costs. The tax credit and drug-plan provisions require analysis; they do not themselves create a tax credit or add treatments to a drug plan.